Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 1 min ago
Peer-reviewedCC BY 4.0Frontiers in Medicine

Pneumovesicoscopic en bloc resection of multifocal bladder paraganglioma: a case report

  1. 1Department of Urology, First People's Hospital of Kunshan, Kunshan, China

Abstract

Background: Bladder paraganglioma is a rare non-epithelial neuroendocrine tumor. Catecholamine release may cause micturition-related headache, palpitations, sweating, paroxysmal hypertension, or syncope, but cases without typical symptoms can be difficult to recognize before surgery. Complete surgical excision remains the mainstay of treatment.

Case presentation: A 75-year-old woman was admitted after two bladder lesions were detected. She had no hematuria, lower urinary tract symptoms, or micturition-related headache, palpitations, sweating, or paroxysmal hypertension. Contrast-enhanced CT showed two hypervascular nodules near the bladder neck and on the left posterior wall, measuring 12 × 14 mm and 6 × 9 mm, respectively. Twenty-four-hour urinary free catecholamines were within the reference ranges. Plasma free normetanephrine was mildly elevated at 0.96 nmol/L (upper reference limit, 0.71 nmol/L; approximately 1.35 × ULN) when measured by LC-MS/MS under standardized sampling conditions, whereas plasma metanephrine and 3-methoxytyramine remained within their reference ranges. This profile was considered consistent with a clinically silent but mildly biochemically functional tumor. The patient underwent pneumovesicoscopic en bloc resection. Histopathology confirmed multifocal bladder paraganglioma confined to the submucosa, with negative surgical margins, a Ki-67 proliferation index <1%, and retained SDHB expression. Recovery was uneventful, and cystoscopy showed no recurrence at 12 months.

Conclusions: Bladder paraganglioma should be considered in a hypervascular submucosal bladder mass with intact overlying mucosa even when typical catecholamine-related symptoms are absent. This single case supports the technical feasibility of pneumovesicoscopic en bloc resection for selected localized lesions, but the 12-month follow-up is insufficient to establish comparative effectiveness or long-term oncologic safety.

Related

  1. Primary Cardiac Paraganglioma Management and Resection With Rare Recurrent Metastasis
    Ashley B. Chuong, Marcell Szekely, Maria G. Lopez-Trevino +3
    JACC Case ReportsPeer-reviewedCC BY-NC-ND 4.0Full textCardiovascular medicinePMCDOAJ
  2. Left ventricular thrombus formation in paraganglioma: a rare but serious complication – a case report
    Abdulrahman Alsbikhan, Hrag Altounian, Edward Marashly +4
    Annals of medicine and surgery (2012)Peer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Minimally invasive resection of multifocal duodeno-jejunal gastrointestinal stromal tumors in neurofibromatosis type 1
    Laura Samà, Federica Bezzi, Marta Casiraghi +7
    Frontiers in OncologyPeer-reviewedCC BY 4.0OncologyCrossref
  4. Blue versus white light for transurethral resection of non-muscle invasive bladder cancer
    Philipp Maisch, Mohammad Hamidi Madani, Alex Koziarz +3
    Cochrane Database of Systematic ReviewsPeer-reviewedPublisher termsFull text19 citedOncologyOpenAlexPMC
  5. Porta Hepatis Paraganglioma: A Rare Case Report With Diagnostic Pitfalls.
    Maryam Vajihinejad, Soroosh Najafi, Amirpasha Amlelshahbaz +1
    Case reports in pathologyPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
BibTeX
@article{wang2026pneumovesicoscopic,
  title = {{Pneumovesicoscopic en bloc resection of multifocal bladder paraganglioma: a case report}},
  author = {Bing Wang and Yu Hong and Tianhai Liao and Dingli Hu and Yunlong Li},
  journal = {Frontiers in Medicine},
  year = {2026},
  month = oct,
  doi = {10.3389/fmed.2026.1992514},
  url = {https://doi.org/10.3389/fmed.2026.1992514},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Pneumovesicoscopic en bloc resection of multifocal bladder paraganglioma: a case report
AU  - Bing Wang
AU  - Yu Hong
AU  - Tianhai Liao
AU  - Dingli Hu
AU  - Yunlong Li
PY  - 2026
DA  - 2026/10/21
JO  - Frontiers in Medicine
DO  - 10.3389/fmed.2026.1992514
UR  - https://doi.org/10.3389/fmed.2026.1992514
AB  - Background: Bladder paraganglioma is a rare non-epithelial neuroendocrine tumor. Catecholamine release may cause micturition-related headache, palpitations, sweating, paroxysmal hypertension, or syncope, but cases without typical symptoms can be difficult to recognize before surgery. Complete surgical excision remains the mainstay of treatment.  Case presentation: A 75-year-old woman was admitted after two bladder lesions were detected. She had no hematuria, lower urinary tract symptoms, or micturition-related headache, palpitations, sweating, or paroxysmal hypertension. Contrast-enhanced CT showed two hypervascular nodules near the bladder neck and on the left posterior wall, measuring 12 × 14 mm and 6 × 9 mm, respectively. Twenty-four-hour urinary free catecholamines were within the reference ranges. Plasma free normetanephrine was mildly elevated at 0.96 nmol/L (upper reference limit, 0.71 nmol/L; approximately 1.35 × ULN) when measured by LC-MS/MS under standardized sampling conditions, whereas plasma metanephrine and 3-methoxytyramine remained within their reference ranges. This profile was considered consistent with a clinically silent but mildly biochemically functional tumor. The patient underwent pneumovesicoscopic en bloc resection. Histopathology confirmed multifocal bladder paraganglioma confined to the submucosa, with negative surgical margins, a Ki-67 proliferation index <1%, and retained SDHB expression. Recovery was uneventful, and cystoscopy showed no recurrence at 12 months.  Conclusions: Bladder paraganglioma should be considered in a hypervascular submucosal bladder mass with intact overlying mucosa even when typical catecholamine-related symptoms are absent. This single case supports the technical feasibility of pneumovesicoscopic en bloc resection for selected localized lesions, but the 12-month follow-up is insufficient to establish comparative effectiveness or long-term oncologic safety.
SN  - 2296-858X
ER  -